A Phase1b Clinical Study of the Oral PI3Kd Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

被引：1
|
作者：
Qiu, Lugui [1 ,2 ]
Li, Zhiming [3 ]
Huang, Yunhong [4 ]
Liu, Ligen [5 ]
Liu, Lihong [6 ]
Guo, Ye [7 ]
Deng, Lan [8 ]
Yang, Haiyan [9 ]
CA, Zhen, I [10 ,12 ]
Ye, Xu [11 ]
Wang, Zhen
Bao, Hanying [13 ]
Xu, Zusheng [13 ]
Zheng, Binghua [13 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[4] Guizhou Med Univ, Dept Lymphoma, Affiliated Canc Hosp, Guiyang, Peoples R China
[5] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[6] Hebei Med Univ, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[7] Tongji Univ, Shanghai Dongfang Hosp, Dept Med Oncol, Shanghai, Peoples R China
[8] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Hematol, Sch Med, Shanghai, Peoples R China
[9] Univ Chinese Acad Sci, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China
[12] Linyi Canc Hosp, Linyi, Peoples R China
[13] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148276
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3576
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas
    Zhu, Jun
    Cao, Junning
    Qiu, Lugui
    Qi, Junyuan
    Song, Yuqin
    Tu, Meifeng
    Ji, Dongmei
    Shen, Weina
    Sun, Mingyuan
    Hua, Ye
    Yang, Chen
    Yu, Chen
    Wang, Jian
    Dai, Guangxiu
    Su, Weiguo
    BLOOD, 2018, 132
  • [22] A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
    Samaniego, Felipe
    Sadiq, Ahad A.
    Mahadevan, Daruka
    Koontz, Michael Z.
    Villasboas, Jose C.
    Burke, John M.
    Reid, Erin G.
    Cherry, Mohamad
    Melear, Jason
    Priego, Victor
    Cobb, Patrick
    Cull, Elizabeth H.
    Conkling, Paul
    Cosgrove, David
    Roeker, Lindsey E.
    Haney, Donna Nguyen
    Hu, Jia
    Sinha, Ranjeet Kumar
    Rice, William G.
    Bejar, Rafael
    BLOOD, 2022, 140 : 6498 - 6500
  • [23] A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma
    Shah, N. K.
    Rule, S.
    Salles, G.
    Karlin, L.
    Morschhauser, F.
    Terriou, L.
    Dyer, M.
    Hutchinson, C.
    Fegan, C.
    Davison, A.
    Cartron, G.
    Wright, J. G.
    Saunders, A.
    Honda, H.
    Ono, T.
    Sharpe, J.
    Yoshizawa, T.
    Yasuhiro, T.
    Birkett, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 57 - 58
  • [24] Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kd) in patients with uveal melanoma and advanced cancers
    Di Giacomo, Anna Maria
    Simonelli, Matteo
    Santangelo, Federica
    Amato, Giovanni
    Simonetti, Elena
    Graham, Jill
    Lahn, Michael M. F.
    Di Conza, Giusy
    Hammett, Tracey
    Zorrilla, Rebeca
    Durini, Marco
    Tan, Ziyang
    Tadepally, Lakshmikanth
    Brodin, Petter
    Occhipinti, Mariaelena
    Carlo-Stella, Carmelo
    Santoro, Armando
    Spiliopoulou, Pavlina
    Evans, T. R. Jeffry
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] RP5237-a Novel, Selective, and Potent Inhibitor of PI3Kdelta With Therapeutic Potential in B-cell Lymphomas
    Viswanadha, S.
    Prasanna, R.
    Muthuppalaniappan, M.
    Babu, G.
    Varanasi, K.
    Veeraraghavan, S.
    Vakkalanka, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S144 - S144
  • [26] A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.
    Jin, Jie
    Cen, Hong
    Zhou, Keshu
    Xu, Xiaohong
    Li, Fei
    Wu, Tao
    Yang, Haiyan
    Wang, Zheng
    Li, Zhiming
    Qiu, Lugui
    Bao, Hanying
    Xu, Zusheng
    Shu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies.
    Qiu, Lugui
    Qi, Junyuan
    Song, Yuqin
    Jiang, Bo
    Tu, Meifeng
    Ping, Lingyan
    Li, Zengjun
    Zhu, Jun
    Xu, Yuanyuan
    Bao, Hanying
    Xu, Zusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina
    Buergesser, Maria Virginia
    Gualco, Gabriela
    Diller, Ana
    Natkunam, Yasodha
    Bacchi, Carlos E.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2013, 17 (03) : 250 - 255
  • [29] PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
    Sun, Peng
    Cen, Hong
    Yang, Haiyan
    Huang, Rui
    Cai, Zhen
    Gu, Xuekui
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    Li, Zhi-Ming
    CANCER CELL INTERNATIONAL, 2025, 25 (01)
  • [30] Coastal: A Phase 3 Study of the PI3Kd Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
    Jurczak, Wojciech
    Zinzani, Pier Luigi Luigi
    Cunningham, David
    Azoulay, Michel
    Huang, Wenying
    Xu, Weiming
    Ribrag, Vincent
    BLOOD, 2021, 138
12345